newsfilter
← Latest News
GlobeNewswire·

Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm

  • Kuehn Law, PLLC is investigating potential fiduciary duty breaches by officers & directors of Corcept Therapeutics Incorporated (NASDAQ: CORT).
  • The investigation centers on alleged failure to disclose FDA concerns regarding the adequacy of the clinical development program for relacorilant.
  • Corcept allegedly touted expected FDA approval for relacorilant while concealing the material risk of rejection for the New Drug Application.
  • Shareholders who purchased CORT stock prior to October 31, 2024, may contact Justin Kuehn, Esq. to participate in the litigation.
  • Kuehn Law covers all case costs & does not charge investor clients for representation.
  • Shareholders are urged to contact the firm immediately due to potential time limits on enforcing rights.